MAIA Biotechnology, Inc.
AMEX:MAIA · New York Stock Exchange American
+$0.05 today
Vol 0.48M · Avg 0.78M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-942.7%
avg -298.6%
ROIC
-627.4%
avg -238.6%
ROA
-230.8%
avg -318.0%
Analysis
ROA is currently the strongest return metric at -230.8% versus its period average of -318.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Vlad Vitoc | Co-Founder, President, Chief Executive Officer & Chairman of the Board of Directors | $960,152.00 | — | 56 | $976,121.00 | 1.61% |
Sergei Gryaznov | Chief Scientific Officer | $705,054.00 | — | 66 | $46,511.00 | 0.08% |
Jeffrey C. Himmelreich | Head of Finance and Principal Financial & Accounting Officer | $351,386.00 | — | 50 | $60,000.00 | 0.10% |
Linda Moreira | Company Secretary | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
26
$990,029.63
Sells
0
$0.00
Net Sentiment
+$990,029.63
Net buying
Most Active
Smith Stan
11 transactions
1–10 of 26
Analysis
Insiders reported 26 buys worth $990,029.63 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $990,029.63. Smith Stan was the most active insider with 11 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A0 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Who manages MAIA?
MAIA Biotechnology, Inc. (MAIA) lists 4 active executives. The top listed executive is Sergei Gryaznov, Chief Scientific Officer.
Are MAIA insiders buying or selling?
Recent insider activity shows net buying of $15.90M.
Explore More
Continue the stock analysis
Jump to another research area for this company.